School of Medicine
Showing 1-5 of 5 Results
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly InterestsRecent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program creates, develops and optimizes genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, while simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
Assistant Professor of Pediatrics (Hematology/Oncology) at the Stanford University Medical Center
BioRobbie Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. After graduating with a BA from Columbia University, Dr. Majzner attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells, children with B cell acute lymphoblastic leukemia (B-ALL) who often had no other therapeutic option. Witnessing the success of CAR T cells in these patients drove Dr. Majzner to the laboratory, where he focuses on extending the use of CAR T cells to solid tumors. He has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2 (Mount/Majzner et al., Nature Medicine, 2018) B7-H3 (Majzner et al., Clinical Cancer Research, 2019), and ALK (Walker/Majzner et al., Molecular Therapy, 2017). Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting (Majzner et al., Cancer Discovery, 2020). By drawing on state of the art bioengineering techniques, the Majzner Laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer.
Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology.
Assistant Professor of Medicine (Blood and Marrow Transplantation) and of Pediatrics (Stem Cell Transplantation) at the Stanford University Medical Center
Current Research and Scholarly InterestsResearch focus in T cell immunotherapy and T cell immune monitoring using high-throughput sequencing and genomic approaches, with an emphasis on hematopoietic stem cell transplantation, the treatment of graft-versus-host disease and immune tolerance induction.
Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Current Research and Scholarly InterestsDr. Miklos is the Clinical Director of Stanford University’s Center for Cancer Cell Therapy, and leads Stanford’s CAR therapy clinical trials for patients with aggressive lymphomas: 1) Phase I CAR19-22 Safety and efficacy outcomes – the first bispecific CAR-T study for patients with rel/refractory DLBCL and ALL, 2) CAR19 CD4-CD8 immune phenotyping following various CAR-T, 3) Mechanisms for CAR-T DLBCL treatment Failure
Assistant Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center
Current Research and Scholarly InterestsDr. Muffly's interests include health services research and clinical trials with a focus on acute leukemia and blood and marrow transplantation.